Drug intelligence / Profile preview

metoprolol + sibutramine

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of metoprolol, a cardio-selective beta-blocker, and sibutramine, a selective serotonin and norepinephrine reuptake inhibitor used for weight loss. The addition of low-dose metoprolol (typically 25 mg/day) to sibutramine therapy (typically 10 mg/day) helps mitigate cardiovascular side effects of sibutramine such as hypertension and palpitations, while maintaining weight loss efficacy. This combination has been shown to increase patient compliance and decrease dropout rates in obesity treatment.

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)ADRB1 (β1)

Beyond the preview

Go deeper on metoprolol + sibutramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metoprolol + sibutramine.

Explore the full profile